Co-Diagnostics EBIT per Share
The EBIT per Share of Co-Diagnostics (CODX) as of Oct 8, 2026 is -23.52 USD. In the previous year, EBIT per Share was -36.38 USD — a change of -35.35% (higher).
Get this data via API
Financial Data API
EBIT per Share
-23.52USD
YoY
-35.35%
Last updated:
EBIT per Share of Co-Diagnostics is 2025 -23.52 USD. EBIT per Share of Co-Diagnostics was 2024 -36.38 USD. It decreases by -35.35% higher compared to the previous year.
The Co-Diagnostics EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-40.98 USD
Jan 1, 2024
-36.38 USD
Jan 1, 2025
-23.52 USD
Jan 1, 2026 (e)
-0.24 USD
Jan 1, 2027 (e)
-7.42 USD
Jan 1, 2028 (e)
-25.64 USD
Jan 1, 2029 (e)
-58.99 USD
Jan 1, 2031 (e)
0.00 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.00USD | -100.00% |
| est | -58.99USD | +130.09% |
| est | -25.64USD | +245.43% |
| est | -7.42USD | +3,011.15% |
| est | -0.24USD | -98.99% |
| -23.52USD | -35.35% | |
| -36.38USD | -11.24% | |
| -40.98USD | +56.33% | |
| -26.22USD | -156.82% | |
| 46.14USD | +3.59% | |
| 44.54USD | -656.42% | |
| -8.00USD | +1,995.68% | |
| -0.38USD | -97.64% | |
| -16.19USD | +253.71% | |
| -4.58USD | -26.56% | |
| -6.23USD | +2,497.44% | |
| -0.24USD | — |
Access this data via the Eulerpool API
Co-Diagnostics Stock analysis
What does Co-Diagnostics do? Co-Diagnostics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Co-Diagnostics stock
EBIT per Share of Co-Diagnostics is -23.52 USD in 2025.
EBIT per Share of Co-Diagnostics changed from -36.38 USD to -23.52 USD, representing a -35.35% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Co-Diagnostics
All Key Metrics — Co-Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth